These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 20131077)

  • 1. Modulating the pharmacokinetics of therapeutic antibodies.
    Constantinou A; Chen C; Deonarain MP
    Biotechnol Lett; 2010 May; 32(5):609-22. PubMed ID: 20131077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Site-specific polysialylation of an antitumor single-chain Fv fragment.
    Constantinou A; Epenetos AA; Hreczuk-Hirst D; Jain S; Wright M; Chester KA; Deonarain MP
    Bioconjug Chem; 2009 May; 20(5):924-31. PubMed ID: 19402707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The pharmacokinetics of monoclonal antibodies].
    Keizer RJ; Huitema AD; Damen CW; Schellens JH; Beijnen JH
    Ned Tijdschr Geneeskd; 2007 Mar; 151(12):683-8. PubMed ID: 17447593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
    Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
    J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibody pharmacokinetics and pharmacodynamics.
    Wang W; Wang EQ; Balthasar JP
    Clin Pharmacol Ther; 2008 Nov; 84(5):548-58. PubMed ID: 18784655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulating antibody pharmacokinetics using hydrophilic polymers.
    Chen C; Constantinou A; Deonarain M
    Expert Opin Drug Deliv; 2011 Sep; 8(9):1221-36. PubMed ID: 21854300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of antibody pharmacokinetics by chemical polysialylation.
    Constantinou A; Epenetos AA; Hreczuk-Hirst D; Jain S; Deonarain MP
    Bioconjug Chem; 2008 Mar; 19(3):643-50. PubMed ID: 18307285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates.
    Yang Z; Wang J; Lu Q; Xu J; Kobayashi Y; Takakura T; Takimoto A; Yoshioka T; Lian C; Chen C; Zhang D; Zhang Y; Li S; Sun X; Tan Y; Yagi S; Frenkel EP; Hoffman RM
    Cancer Res; 2004 Sep; 64(18):6673-8. PubMed ID: 15374983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment.
    Olafsen T; Kenanova VE; Wu AM
    Nat Protoc; 2006; 1(4):2048-60. PubMed ID: 17487194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
    Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
    Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine plays a dominant functional role in the paratope of a synthetic antibody derived from a four amino acid code.
    Fellouse FA; Barthelemy PA; Kelley RF; Sidhu SS
    J Mol Biol; 2006 Mar; 357(1):100-14. PubMed ID: 16413576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.
    Petkova SB; Akilesh S; Sproule TJ; Christianson GJ; Al Khabbaz H; Brown AC; Presta LG; Meng YG; Roopenian DC
    Int Immunol; 2006 Dec; 18(12):1759-69. PubMed ID: 17077181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New strategy for the extension of the serum half-life of antibody fragments.
    Trüssel S; Dumelin C; Frey K; Villa A; Buller F; Neri D
    Bioconjug Chem; 2009 Dec; 20(12):2286-92. PubMed ID: 19916518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments.
    Ochs HR; Smith TW
    J Clin Invest; 1977 Dec; 60(6):1303-13. PubMed ID: 914999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PEGylation of therapeutic proteins.
    Jevsevar S; Kunstelj M; Porekar VG
    Biotechnol J; 2010 Jan; 5(1):113-28. PubMed ID: 20069580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered protein scaffolds as next-generation antibody therapeutics.
    Gebauer M; Skerra A
    Curr Opin Chem Biol; 2009 Jun; 13(3):245-55. PubMed ID: 19501012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G.
    Stork R; Müller D; Kontermann RE
    Protein Eng Des Sel; 2007 Nov; 20(11):569-76. PubMed ID: 17982179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties.
    Herbette LG; Vecchiarelli M; Sartani A; Leonardi A
    Blood Press Suppl; 1998; 2():10-7. PubMed ID: 9850437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of plasma exchange and rituximab for the treatment of thrombotic thrombocytopenic purpura.
    Boctor FN; Smith JA
    Am J Clin Pathol; 2006 Dec; 126(6):965; author reply 965-6. PubMed ID: 17153777
    [No Abstract]   [Full Text] [Related]  

  • 20. Mathematical modeling as accounting: predicting the fate of serum proteins and therapeutic monoclonal antibodies.
    Gurbaxani B
    Clin Immunol; 2007 Feb; 122(2):121-4. PubMed ID: 17126081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.